+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Blood Transfusion Devices Market - Growth, Trends, and Forecasts (2020 - 2025)

  • ID: 4520154
  • Report
  • May 2020
  • Region: Global
  • 116 pages
  • Mordor Intelligence
1 of 5

Enquire about COVID-19 updates for this product.

Enquire Now


  • B. Braun Melsungen AG
  • Becton Dickinson
  • Fresenius Kabi
  • Grifols SA
  • Haemonetics Corporation
  • Immucor Inc.
  • MORE
Certain factors driving market growth are an increasing number of surgical procedures, increasing accidents and trauma cases, the rise in a number of blood disorders, and technological development.

The most commonly performed surgeries that require blood transfusion include cardiovascular procedures, C-section procedures, and trauma and accident injuries. As per estimates by the NIH, and National Heart, Lung, and Blood Institute, blood transfusions are very common in the United States, as each year, over 5 million Americans need blood transfusions. A majority of the surgeries performed are for cardiovascular interventions. Also, due to natural calamities and widespread causalities, the demand for blood transfusion is increasing across the globe.

The rise in the number of blood disorders, such as anemia, leukopenia, erythrocytosis, leukocytosis, and thrombocytosis is also boosting the blood transfusion market. As per the WHO, most children with thalassemia are born in low-income countries, where access to blood transfusion is difficult or is available to only a small percentage of the population.

Key Market Trends

The Pathogen Reduction System is Expected to Witness Healthy Growth

The pathogen reduction system segment of the blood transfusion market is believed to witness a healthy growrh over the forecast period. The demand for pathogen reduction system is growing with the emergence of a cost-effective and innovative solution to inactivate or reduce the risk of infection. For example, the INTERCEPT Blood System from Cerus Corporation has significantly enhanced blood safety at more than 100 blood centers, worldwide.

It is used primarily for the treatment of leukostasis, caused by elevated white blood count in leukemia. It is also used in severe rheumatoid arthritis, to reduce the risk of antibody-mediated rejection of organ during, systemic lupus, Goodpasture syndrome, polymyositis or dermatomycosis, and preeclampsia and eclampsia in pregnancy.

North America Dominates the Blood Transfusion Devices Market

North America currently dominates the market for blood transfusion devices and is expected to remain strong in the future due to an increasing number of trauma cases and surgical procedures, which are driving the demand for blood transfusion. The United States holds the majority of the market in North America. As per the estimates of the American National Red Cross, approximately 36,000 units of red blood cells are needed every day, and nearly 21 million blood components are transfused each year in the United States. This indicates the high demand for blood transfusion in the country. These statistics also indicate the high requirement for blood transfusion products. Thus, ensuring a consistent supply of these products is crucial to support the growing healthcare requirements in the region.

Competitive Landscape

The blood transfusion market is moderately competitive and consists of several major players. However, with technological advancements and product innovation, mid-size to smaller companies are increasing their market presence by introducing new products with cost-effective pricing. Companies like Immucor Inc., Becton Dickinson, B. Braun, Terumo Corporation, and Grifols SA., hold a significant share in the blood transfusion market.

Reasons to Purchase this report:
  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support
Note: Product cover images may vary from those shown
2 of 5


  • B. Braun Melsungen AG
  • Becton Dickinson
  • Fresenius Kabi
  • Grifols SA
  • Haemonetics Corporation
  • Immucor Inc.
  • MORE
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study



4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Number of Surgical Procedures
4.2.2 Rise in the Number of Blood Disorders
4.2.3 Technological Advancements in the Devices
4.3 Market Restraints
4.3.1 Stringent Regulatory Framework
4.3.2 High Costs Associated with Handling of Blood and its Components
4.4 Industry Attractiveness - Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5.1 By Product
5.1.1 Blood Bag and Accessory
5.1.2 Blood Mixer
5.1.3 Filter
5.1.4 Blood Component Separator
5.1.5 Apheresis Device
5.1.6 Pathogen Reduction System
5.1.7 Consumables and Supplies
5.1.8 Other Products
5.2 By End-user
5.2.1 Hospital
5.2.2 Ambulatory Surgical Centres
5.2.3 Blood Bank
5.2.4 Other End-users
5.3 Geography
5.3.1 North America United States Canada Mexico
5.3.2 Europe Germany United Kingdom France Italy Spain Rest of Europe
5.3.3 Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.3.4 Middle-East & Africa GCC South Africa Rest of Middle-East & Africa
5.3.5 South America Brazil Argentina Rest of South America

6.1 Company Profiles
6.1.1 Immucor Inc.
6.1.2 Becton Dickinson
6.1.3 B. Braun Melsungen AG
6.1.4 Terumo Corporation
6.1.5 Grifols SA
6.1.6 Kaneka Corporation
6.1.7 Fresenius Kabi
6.1.8 Haemonetics Corporation
6.1.9 Macopharma SA

Note: Product cover images may vary from those shown
3 of 5


4 of 5
  • Immucor Inc.
  • Becton Dickinson
  • B. Braun Melsungen AG
  • Terumo Corporation
  • Grifols SA
  • Kaneka Corporation
  • Fresenius Kabi
  • Haemonetics Corporation
  • Macopharma SA
Note: Product cover images may vary from those shown
5 of 5